Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial
Publication
, Conference
Xavier, D; Hanna, M; Wallentin, L; Alexander, J; Lopes, R; Merrill, P; Wojdyla, D; Bahit, C; Hohnloser, S; Granger, C
Published in: EUROPEAN HEART JOURNAL
2016
Duke Scholars
Published In
EUROPEAN HEART JOURNAL
EISSN
1522-9645
ISSN
0195-668X
Publication Date
2016
Volume
37
Start / End Page
507 / 507
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Xavier, D., Hanna, M., Wallentin, L., Alexander, J., Lopes, R., Merrill, P., … Granger, C. (2016). Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial. In EUROPEAN HEART JOURNAL (Vol. 37, pp. 507–507).
Xavier, D., M. Hanna, L. Wallentin, J. Alexander, R. Lopes, P. Merrill, D. Wojdyla, C. Bahit, S. Hohnloser, and C. Granger. “Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial.” In EUROPEAN HEART JOURNAL, 37:507–507, 2016.
Xavier D, Hanna M, Wallentin L, Alexander J, Lopes R, Merrill P, et al. Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial. In: EUROPEAN HEART JOURNAL. 2016. p. 507–507.
Xavier, D., et al. “Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial.” EUROPEAN HEART JOURNAL, vol. 37, 2016, pp. 507–507.
Xavier D, Hanna M, Wallentin L, Alexander J, Lopes R, Merrill P, Wojdyla D, Bahit C, Hohnloser S, Granger C. Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial. EUROPEAN HEART JOURNAL. 2016. p. 507–507.
Published In
EUROPEAN HEART JOURNAL
EISSN
1522-9645
ISSN
0195-668X
Publication Date
2016
Volume
37
Start / End Page
507 / 507
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology